Krystal Biotech Inc annual free cash flow for fiscal TTM was $257 million, an increase of 36.0% from $189 million in fiscal 2025. All figures are reported results from public filings — no estimates or projections.
| Free Cash Flow (annual) | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow (FCF) | $257M | $189M | $119M | ($101M) | ($154M) | ($116M) | ($41M) | ($25M) | ($12M) | ($4M) | ($1M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Free Cash Flow (quarterly) | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow (FCF) | $71M | $73M | $75M | $38M | $51M | $25M | $52M | $58M | ($5M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
More KRYS metrics: Revenue · Gross Profit · Operating Income · Net Income · EPS · EBITDA · Shares Outstanding
All KRYS financial statements → Interactive KRYS charts →
About TickerBase · Data methodology & sources · Privacy · Terms